Drugs for the treatment of diabetes and obesity: announced new prices

GEROPHARM continued the program to increase the availability of obesity and type 2 diabetes. In pharmacy chains and online platforms across Russia, prices for Sejaro, Semavik and Semavik Next were reduced by an average of 20%.

The change in cost affected including the starting dosages of Sejaro, used at the beginning of therapy. As a result, the first stage of treatment can become more comfortable for patients.

GEROPHARM reported that the price reduction is provided by the program to increase the availability of treatment. CEO Peter Rodionov said that the task is not only to provide patients with the necessary drugs, but also to create conditions for long-term lifestyle changes. This is reported by newstula.ru.

The company is also involved in research related to obesity. In April, GEROPHARM and the National Institute of Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation launched the all-Russian study “ORBIT”. The project is aimed at studying the characteristics of overweight in the adult population and assessing the scale of the problem in the country.

Another direction was the evaluation of therapy for adolescents with obesity. GEROPHARM was the first in Russia to start clinical studies of tirzepatide (Sedjaro) and semaglutide (Semavik Next) in this age category. The results of the research can become the basis for the formation of an evidence base and further development of approaches to the treatment of adolescents with obesity.

The company considers pricing as part of its patient support system. The availability of therapy is taken into account when determining the strategy of care.